Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus. A 30-week Randomised, Double-blind, Placebo-controlled Trial
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2018
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN 9
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 08 Aug 2018 Status changed from active, no longer recruiting to completed.
- 06 Jun 2018 Planned End Date changed from 6 Sep 2018 to 13 Aug 2018.